BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 17, Issue 12
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (0)
All Articles published online
The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-10) series.
Item 
Count 
PDF1
HTML21
Figures (1-5)0
Tables (1-10)0
 Sum=22
Featured Article
The chart showing Browse series, Download series.
Item 
Count 
Browse6
Download16
 Sum=22
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse4
Download1
 Sum=5
Dec 27, 2025 (publication date) through Dec 25, 2025
Times Cited of This Article
  • Times Cited  (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Surgery
ISSN
1948-9366
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastrointest Surg. Dec 27, 2025; 17(12): 113940
Published online Dec 27, 2025. doi: 10.4240/wjgs.v17.i12.113940
Table 1 Comparison of the baseline characteristics between the robotic liver resection and robotic intraoperative radiofrequency ablation groups before and after matching in de novo data, n (%)/median (interquartile range)
Variable
Before PS matching
After PS matching
RIO-RFA (n = 8)
R-LR (n = 49)
P value
RIO-RFA (n = 8)
R-LR (n = 8)
P value
Age (years)71.5 (68.5-74.2)68.0 (62.0-77.0)0.62171.5 (68.5-74.2)68.0 (58.8-77.5)0.713
Male5 (62.5)31 (63.3)15 (62.5)5 (62.5)1
Height (cm)164.5 (159.8-170.2)162.0 (157.0-168.0)0.4009164.5 (159.8-170.2)162.0 (156.5-166.5)0.4613
Weight (kg)66.5 (64.8-71.0)66.0 (53.0-75.0)0.542466.5 (64.8-71.0)60.0 (52.8-69.8)0.3998
BMI (kg/m2)24.5 (23.0-25.4)23.4 (20.8-26.9)0.611624.5 (23.0-25.4)23.0 (21.1-24.8)0.3823
HBV5 (62.5)33 (67.3)15 (62.5)6 (75.0)1
HCV3 (37.5)13 (26.5)0.67353 (37.5)2 (25.0)1
ICG-R15 < 10%1 (12.5)16 (32.7)0.41331 (12.5)2 (25.0)1
Platelet (103/mL)127.5 (97.2-156.5)169.0 (135.0-215.0)0.0179127.5 (97.2-156.5)135.5 (110.0-160.0)0.713
Prothrombin time (s)10.8 (10.7-11.1)10.6 (10.3-11.1)0.29510.8 (10.7-11.1)10.8 (10.4-11.0)0.5621
AST (U/L)106.5 (79.0-460.8)244.0 (82.0-511.0)0.5972106.5 (79.0-460.8)329.0 (174.0-857.5)0.1304
ALT (U/L)112.0 (75.2-444.5)307.0 (120.0-532.0)0.2802112.0 (75.2-444.5)366.5 (209.0-1018.8)0.1605
AFP ≥ 100 ng/mL2 (25.0)8 (16.3)0.61942 (25.0)1 (12.5)1
Bilirubin total (mg/dL)0.9 (0.8-1.1)0.8 (0.6-0.9)0.24780.9 (0.8-1.1)0.9 (0.8-1.0)1
Albumin (g/dL)4.2 (4.0-4.6)4.4 (4.1-4.7)0.55674.2 (4.0-4.6)4.6 (4.4-4.7)0.2448
ALBI (grade 1/2)6 (75.0)/2 (25.0)42 (85.7)/7 (14.3)0.5996 (75.0)/2 (25.0)7 (87.5)/1 (12.5)1
Child-Pugh
(class A/B)		7 (87.5)/1 (12.5)48 (98.0)/1 (2.0)0.26327 (87.5)/1 (12.5)8 (100.0)/0 (0.0)1
T stage (1/2/3/4)6 (75.0)/1 (12.5)/0 (0.0)/1 (12.5)36 (73.5)/12 (24.5)/1 (2.0)/0 (0.0)0.08126 (75.0)/1 (12.5)/1(12.5)5 (62.5)/3 (37.5)/0 (0.0)0.3515
Major tumor size (cm)1.6 (1.5-2.3)3.0 (1.8-4.5)0.03431.6 (1.5-2.3)2.1 (1.6-3.0)0.4589
Aggregate tumor size (cm)1.6 (1.6-2.8)3.1 (2.1-4.5)0.0711.6 (1.6-2.8)2.5 (1.9-3.0)0.5249
Tumor numbers
(1/2/3/4)		5 (62.5)/1 (12.5)/1 (12.5)/1 (12.5)39 (79.6)/10 (30.4)/0 (0)/0 (0)0.00535 (62.5)/1 (12.5)/1(12.5)/1 (12.5)7 (87.5)/1 (12.5)/0 (0)/0 (0)0.5062
Multi-tumors3 (37.5)10 (20.4)0.36533 (37.5)1 (12.5)0.5692
BCLC
(stage 0/A/B)		3 (37.5)/4 (50.0)/1 (12.5)9 (18.4)/31 (63.3)/9 (18.4)0.46583 (37.5)/4 (50.0)/1(12.5)2 (25.0)/6 (75.0)/0 (0.0)0.4493
Operation time (minutes)104.0 (68.8-128.8)175.0 (155.0-249.0)0.0002104.0 (68.8-128.8)114.5 (93.0-182.8)0.2698
SAS (score 2/3)5 (62.5)/3 (37.5)26 (53.1)/23 (46.9)0.71535 (62.5)/3 (37.5)4 (50.0)/4 (50.0)1
Blood loss (mL)10.0 (10.0-10.0)350.0 (105.0-805.0)0.000310.0 (10.0-10.0)80.0 (10.0-117.5)0.1179
Blood transfusion2 (25.0)31 (63.3)/18 (36.7)0.69932 (25.0)2 (25.0)1
Complication1 (12.5)11 (22.4)11 (12.5)2 (25.0)1
Hospital stays (days)9.5 (9.0-10.0)11.0 (9.0-14.0)0.36049.5 (9.0-10.0)10.5 (10.0-13.5)0.1151
BMI: Body mass index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ICG-R15: Indocyanine green retention rate at 15 minutes; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AFP: Alpha-fetoprotein; ALBI: Albumin-Bilirubin grade; BCLC: Barcelona Clinic Liver Cancer; SAS: Surgical Apgar Score; PS: Propensity score; RIO-RFA: Robotic intraoperative RFA; R-LR: Robotic liver resection.
Full Size Table
Table 2 Comparison of the baseline characteristics between the robotic liver resection and robotic intraoperative radiofrequency ablation groups before and after matching in first recurrence data, n (%)/median (interquartile range)
Variable
Before PS matching
After PS matching
RIO-RFA (n = 8)
R-LR (n = 49)
P value
RIO-RFA (n = 8)
R-LR (n = 8)
P value
Age (years)71.5 (62.8-75.0)68.0 (63.0-75.5)0.860871.5 (62.8-75.0)67.0 (63.0-74.0)0.7769
Male14 (87.5)16 (80.0)0.672214 (87.5)13 (81.2)1
Height (cm)164.0 (157.2-170.5)166.5 (158.8-169.2)0.8984164.0 (157.2-170.5)167.5 (163.2-169.2)0.7196
Weight (kg)64.5 (54.5-78.5)65.5 (61.5-75.0)0.725864.5 (54.5-78.5)71.2 (63.8-75.2)0.4063
BMI (kg/m2)25.9 (20.7-27.0)26.2 (23.1-26.9)0.690625.9 (20.7-27.0)26.3 (24.5-27.0)0.534
HBV8 (50.0)14 (70.0)0.37938 (50.0)10 (62.5)0.7216
HCV4 (25.0)6 (30.0)14 (25.0)6 (37.5)0.7043
ICG-R15 < 10%5 (31.2)7 (35.0)15 (31.2)3 (18.8)0.6851
Platelet (103/mL)116.5 (89.5-151.5)123.0 (103.8-156.5)0.4737116.5 (89.5-151.5)117.5 (98.0-145.0)0.91
Prothrombin time (s)10.9 (10.5-11.0)10.5 (10.3-10.9)0.086710.9 (10.5-11.0)10.6 (10.4-10.9)0.2882
AST (U/L)323.0 (155.2-1067.2)194.0 (126.0-323.0)0.1345323.0 (155.2-1067.2)204.0 (126.8-323.0)0.2
ALT (U/L)266.5 (174.0-762.0)274.5 (130.0-437.5)0.4544266.5 (174.0-762.0)225.5 (130.0-384.2)0.3558
AFP ≥ 100 ng/mL4 (25.0)5 (25.0)14 (25.0)4 (25.0)1
Bilirubin total (mg/dL)1.0 (0.6-1.4)0.9 (0.7-1.1)0.39731.0 (0.6-1.4)0.9 (0.7-1.1)0.5962
Albumin (g/dL)4.5 (4.0-4.6)4.3 (4.0-4.7)0.77364.5 (4.0-4.6)4.5 (4.1-4.7)0.4602
ALBI (grade 1/2)12 (75.0)/4 (25.0)16 (80.0)/4 (20.0)112 (75.0)/4 (25.0)13 (81.2)/3 (18.8)1
Child-Pugh
(class A/B)		12 (75.0)/4 (25.0)18 (90.0)/2 (10.0)0.373812 (75.0)/4 (25.0)14 (87.5)/2 (12.5)0.6539
T stage (1/2/3/4)5 (31.2)/10 (62.5)/1 (6.2)13 (65.0)/6 (30.0)/1 (5.0)0.12485 (31.2)/10 (62.5)/1 (6.2)11 (68.8)/4 (25.0)/1 (6.2)0.0898
Major tumor size (cm)2.3 (1.7-2.7)1.9 (1.5-2.8)0.51332.3 (1.7-2.7)1.9 (1.3-2.2)0.2993
Aggregate tumor size (cm)3.3 (2.4-5.3)2.0 (1.8-3.4)0.05813.3 (2.4-5.3)1.9 (1.6-2.7)0.0184
Tumor numbers
(1/2/3/4/5)		7 (43.8)/4 (25.0)/3 (18.8)/1 (6.2)/1 (6.2)13 (65.0)/5 (25.0)/2 (10.0)/0 (0)/0 (0)0.44637 (43.8)/4 (25.0)/3 (18.8)/1 (6.2)/1 (6.2)11 (68.8)/3 (18.8)/2 (12.5)/0 (0)/0 (0)0.5198
Multi-tumors9 (56.2)7 (35.0)0.34859 (56.2)5 (31.2)0.285
BCLC (stage 0/A/B)1 (6.2)/12 (75.0)/3 (18.8)6 (30.0)/12 (60.0)/2 (10.0)0.18561 (6.2)/12 (75.0)/3 (18.8)6 (37.5)/9 (56.2)/1 (6.2)0.0821
Operation time (minutes)109.5 (100.0-175.5)167.5 (128.5-197.2)0.1043109.5 (100.0-175.5)164.5 (128.5-176.0)0.1998
SAS (score 2/3)9 (56.2)/7 (43.8)12 (60.0)/8 (40.0)19 (56.2)/7 (43.8)11 (68.8)/5 (31.2)0.715
Blood loss (mL)10.0 (10.0-55.0)175.0 (77.5-326.2)0.004610.0 (10.0-55.0)175.0 (10.0-266.2)0.0174
Blood transfusion5 (31.2)7 (35.0)15 (31.2)5 (31.2)1
Complication5 (31.2)2 (10.0)0.20365 (31.2)2 (12.5)0.3944
Hospital stays (days)8.0 (7.0-11.0)9.0 (7.8-12.0)0.38578.0 (7.0-11.0)9.0 (7.8-10.5)0.5055
BMI: Body mass index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; ICG-R15: Indocyanine green retention rate at 15 minutes; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AFP: Alpha-fetoprotein; ALBI: Albumin-Bilirubin grade; BCLC: Barcelona Clinic Liver Cancer; SAS: Surgical Apgar Score; PS: Propensity score; RIO-RFA: Robotic intraoperative RFA; R-LR: Robotic liver resection.
Full Size Table
Table 3 Univariate and multivariate analysis of prognostic factors for overall survival in de novo data
Variable
Before PS matching (n = 57)
After PS matching (n = 16)
Univariate
Multivariate
Univariate
Multivariate
HR (95%CI)
P value
HR (95%CI)
P value
HR (95%CI)
P value
HR (95%CI)
P value
Treatment0.61 (0.18-2.14)0.4430.58 (0.10-3.47)0.548
Age1.03 (0.98-1.08)0.1931.04 (0.99-1.10)0.1501.15 (0.97-1.37)0.1071.63 (0.74-3.56)0.224
Gender2.55 (1.00-6.49)0.0504.98 (1.03-24.06)0.0460.57 (0.06-5.12)0.613
HBV0.83 (0.32-2.15)0.7060.81 (0.13-4.89)0.818
HCV0.70 (0.23-2.13)0.5280.36 (0.04-3.27)0.363
ICG-R15 < 10%0.62 (0.20-1.89)0.4030.00 (0.00-inf)0.995
Platelet1.00 (0.99-1.00)0.4581.00 (0.98-1.02)0.988
Prothrombin time1.09 (0.74-1.59)0.6742.80 (0.69-11.37)0.1516.42 (0.17-249.92)0.319
AST1.00 (1.00-1.00)0.9731.00 (1.00-1.00)0.772
ALT1.00 (1.00-1.00)0.8691.00 (1.00-1.00)0.594
AFP ≥ 100 ng/mL1.15 (0.33-3.99)0.8230.00 (0.00-inf)0.996
Bilirubin total0.48 (0.09-2.71)0.4090.30 (0.00-22.14)0.584
Albumin0.55 (0.20-1.53)0.2520.12 (0.01-1.48)0.09831.48 (0.00-3.6 × 109)0.716
ALBI1.56 (0.51-4.73)0.4356.28 (0.86-45.89)0.0730.75 (0.00-8.2 × 106)0.591
Child-Pugh0.00 (0.00-inf)0.9960.00 (0.00-inf)0.996
T stage1.23 (0.62-2.42)0.5540.54 (0.09-3.09)0.489
Major tumor size1.18 (0.97-1.44)0.1061.40 (0.53-3.70)0.4971.64 (0.58-4.62)0.346
Aggregate tumor size1.16 (0.96-1.42)0.1320.95 (0.38-2.37)0.9051.28 (0.46-3.62)0.638
Tumor numbers0.88 (0.34-2.32)0.8000.00 (0.00-inf)0.996
BCLC1.59 (0.72-3.49)0.2490.71 (0.15-3.42)0.67
SAS0.95 (0.38-2.41)0.9172.26 (0.38-13.60)0.373
Complication1.07 (0.31-3.72)0.9116.28 (0.86-45.89)0.070.05 (0.00-2.7 × 1012)0.853
HBV: Hepatitis B virus; HCV: Hepatitis C virus; ICG-R15: Indocyanine green retention rate at 15 minutes; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AFP: Alpha-fetoprotein; ALBI: Albumin-Bilirubin grade; BCLC: Barcelona Clinic Liver Cancer; SAS: Surgical Apgar Score; PS: Propensity score; HR: Hazard ratio; CI: Confidence interval; inf: Infinity.
Full Size Table
Table 4 Univariate and multivariate analysis of prognostic factors for recurrence-free survival in de novo data
Variable
Before PS matching (n = 36)
After PS matching (n = 32)
Univariate
Multivariate
Univariate
Multivariate
HR (95%CI)
P value
HR (95%CI)
P value
HR (95%CI)
P value
HR (95%CI)
P value
Treatment0.13 (0.02-0.66)0.0141.15 (0.01-264.01)0.9600.16 (0.03-0.83)0.0290.92 (0.00-299.08)0.977
Age1.00 (0.95-1.07)0.8861.01 (0.95-1.08)0.782
Gender0.54 (0.07-4.30)0.5560.54 (0.07-4.38)0.565
HBV1.26 (0.31-5.08)0.7421.62 (0.40-6.51)0.498
HCV0.67 (0.14-3.22)0.6140.53 (0.11-2.59)0.436
ICG-R15 < 10%1.82 (0.49-6.80)0.3733.35 (0.88-12.70)0.076100.80 (0.28-36753.83)0.125
Platelet1.00 (0.99-1.01)0.5141.00 (0.99-1.01)0.872
Prothrombin time1.60 (1.11-2.30)0.01116.45 (0.51-528.83)0.1141.55 (1.09-2.20)0.0153.06 (0.10-93.96)0.522
AST1.00 (1.00-1.00)0.1271.00 (0.99-1.01)0.9701.00 (1.00-1.00)0.1801.00 (0.99-1.01)0.643
ALT1.00 (1.00-1.00)0.9551.00 (1.00-1.00)0.882
AFP ≥ 100 ng/mL2.36 (0.63-8.84)0.2032.41 (0.64-9.01)0.1911.65 (0.07-36.92)0.753
Bilirubin total1.15 (0.24-5.58)0.8610.97 (0.19-5.03)0.970
Albumin0.41 (0.12-1.38)0.15026.60 (0.34-2088.41)0.1410.41 (0.13-1.25)0.1157.23 (0.07-799.58)0.410
ALBI1.18 (0.25-5.71)0.8341.31 (0.27-6.34)0.738
Child-Pugh2.08 (0.43-10.07)0.3621.77 (0.37-8.54)0.479
T stage3.79 (1.16-12.31)0.0270.09 (0.00-4.55)0.2253.87 (1.22-12.25)0.0210.31 (0.01-18.91)0.577
Major tumor size1.35 (0.83-2.20)0.2281.51 (0.93-2.43)0.0953.89 (0.07-211.13)0.505
Aggregate tumor size1.30 (1.05-1.61)0.0161.57 (0.70-3.56)0.2761.32 (1.08-1.61)0.0071.33 (0.38-4.66)0.652
Tumor numbers1.70 (0.99-2.91)0.0554.65 (0.77-27.97)0.0931.62 (0.95-2.76)0.07612.29 (0.28-534.39)0.192
BCLC2.87 (0.88-9.38)0.08226.75 (0.89-803.48)0.0583.70 (1.10-12.41)0.0340.99 (0.00-395.47)0.997
SAS0.80 (0.20-3.20)0.7491.00 (0.25-4.01)0.998
Complication7.29 (1.94-27.33)0.003142.17 (0.37-55319.72)0.1036.14 (1.64-23.03)0.0070.42 (0.00-83.99)0.750
HBV: Hepatitis B virus; HCV: Hepatitis C virus; ICG-R15: Indocyanine green retention rate at 15 minutes; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AFP: Alpha-fetoprotein; ALBI: Albumin-Bilirubin grade; BCLC: Barcelona Clinic Liver Cancer; SAS: Surgical Apgar Score; PS: Propensity score; HR: Hazard ratio; CI: Confidence interval.
Full Size Table
Table 5 Univariate and multivariate analysis of prognostic factors for overall survival in first recurrence data
Variable
Before PS matching (n = 57)
After PS matching (n = 16)
Univariate
Multivariate
Univariate
Multivariate
HR (95%CI)
P value
HR (95%CI)
P value
HR (95%CI)
P value
HR (95%CI)
P value
Treatment1.34 (0.41-4.43)0.6311.45 (0.32-6.52)0.626
Age1.01 (0.98-1.05)0.4411.14 (1.00-1.29)0.0561.04 (0.81-1.32)0.769
Gender1.17 (0.55-2.47)0.6790.29 (0.03-2.40)0.249
HBV0.50 (0.24-1.04)0.0640.52 (0.24-1.11)0.0900.20 (0.04-0.95)0.0420.06 (0.00-1.45)0.084
HCV1.38 (0.63-3.03)0.4152.03 (0.45-9.18)0.356
ICG-R15 < 10%0.48 (0.20-1.18)0.1090.73 (0.27-1.99)0.5330.00 (0.00-inf)0.994
Platelet0.99 (0.99-1.00)0.0501.00 (0.99-1.00)0.5161.00 (0.99-1.01)0.7781.12 (0.08-15.00)0.930
Prothrombin time1.85 (1.06-3.23)0.0311.31 (0.77-2.25)0.3193.92 (0.97-15.91)0.056
AST1.00 (1.00-1.00)0.5261.00 (1.00-1.00)0.917
ALT1.00 (1.00-1.00)0.6391.00 (1.00-1.00)0.973
AFP ≥ 100 ng/mL0.69 (0.24-1.99)0.4930.00 (0.00-inf)0.994
Bilirubin total3.31 (0.74-14.89)0.1182.44 (0.42-14.28)0.3217.55 (0.24-234.20)0.249
Albumin0.47 (0.20-1.09)0.0790.65 (0.25-1.71)0.3830.44 (0.07-2.81)0.389
ALBI1.70 (0.69-4.18)0.2492.08 (0.40-10.81)0.383
Child-Pugh0.95 (0.13-7.01)0.9620.00 (0.00-inf)0.995
T stage0.96 (0.52-1.77)0.8990.74 (0.24-2.28)0.602
Major tumor size1.05 (0.89-1.25)0.5391.11 (0.49-2.54)0.802
Aggregate tumor size1.06 (0.90-1.25)0.4571.15 (0.50-2.66)0.747
Tumor numbers1.11 (0.60-2.04)0.7400.59 (0.14-2.56)0.479
BCLC1.09 (0.60-1.97)0.7860.51 (0.13-1.92)0.316
SAS1.73 (0.84-3.55)0.1371.25 (0.57-2.75)0.5744.70 (0.90-24.48)0.0660.94 (0.04-22.31)0.972
Complication0.67 (0.23-1.93)0.4592.08 (0.40-10.81)0.383
HBV: Hepatitis B virus; HCV: Hepatitis C virus; ICG-R15: Indocyanine green retention rate at 15 minutes; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AFP: Alpha-fetoprotein; ALBI: Albumin-Bilirubin grade; BCLC: Barcelona Clinic Liver Cancer; SAS: Surgical Apgar Score; PS: Propensity score; HR: Hazard ratio; CI: Confidence interval.
Full Size Table
Table 6 Univariate and multivariate analysis of prognostic factors for recurrence-free survival in first recurrence data
Variable
Before PS matching (n = 36)
After PS matching (n = 32)
Univariate
Multivariate
Univariate
Multivariate
HR (95%CI)
P value
HR (95%CI)
P value
HR (95%CI)
P value
HR (95%CI)
P value
Treatment0.32 (0.13-0.81)0.0160.29 (0.09-0.97)0.0430.39 (0.15-1.00)0.0510.46 (0.13-1.61)0.226
Age0.99 (0.95-1.03)0.5861.00 (0.96-1.05)0.847
Gender2.77 (0.97-7.95)0.0586.60 (1.79-24.32)0.0043.22 (1.12-9.28)0.0306.81 (1.98-23.41)0.002
HBV0.61 (0.25-1.47)0.2670.74 (0.30-1.82)0.508
HCV1.04 (0.40-2.72)0.9370.88 (0.33-2.33)0.795
ICG-R15 < 10%1.22 (0.48-3.07)0.6752.42 (0.88-6.66)0.0881.33 (0.37-4.84)0.660
Platelet0.99 (0.99-1.00)0.1370.99 (0.98-1.00)0.1291.00 (0.99-1.00)0.321
Prothrombin time1.35 (0.95-1.92)0.0981.21 (0.88-1.66)0.2351.29 (0.90-1.87)0.1671.28 (0.91-1.80)0.153
AST1.00 (1.00-1.00)0.4181.00 (1.00-1.00)0.672
ALT1.00 (1.00-1.00)0.741.00 (1.00-1.00)0.782
AFP ≥ 100 ng/mL2.09 (0.82-5.32)0.122.60 (0.72-9.44)0.1452.69 (1.04-6.97)0.0412.08 (0.54-8.01)0.285
Bilirubin total1.72 (0.63-4.70)0.2931.26 (0.43-3.70)0.675
Albumin0.69 (0.24-1.98)0.4910.63 (0.23-1.73)0.369
ALBI1.44 (0.52-3.97)0.4821.28 (0.42-3.88)0.66
Child-Pugh1.32 (0.38-4.53)0.6581.15 (0.33-3.98)0.824
T stage1.36 (0.60-3.08)0.4551.34 (0.59-3.04)0.482
Major tumor size1.01 (0.67-1.53)0.9511.08 (0.68-1.71)0.743
Aggregate tumor size1.08 (0.89-1.32)0.4361.12 (0.93-1.35)0.214
Tumor numbers1.30 (0.85-1.98)0.2241.30 (0.87-1.95)0.202
BCLC1.08 (0.50-2.31)0.8431.41 (0.64-3.14)0.397
SAS0.74 (0.29-1.85)0.5141.02 (0.40-2.60)0.967
Complication4.20 (1.65-10.70)0.0033.62 (1.09-11.96)0.0343.78 (1.46-9.75)0.0063.08 (0.76-12.44)0.114
HBV: Hepatitis B virus; HCV: Hepatitis C virus; ICG-R15: Indocyanine green retention rate at 15 minutes; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; AFP: Alpha-fetoprotein; ALBI: Albumin-Bilirubin grade; BCLC: Barcelona Clinic Liver Cancer; SAS: Surgical Apgar Score; PS: Propensity score; HR: Hazard ratio; CI: Confidence interval.
Full Size Table
Table 7 Log-rank test results comparing overall survival between unstratified and risk-stratified subgroups of the robotic liver resection group in the de novo group prior to propensity score matching
Gender
Major tumor size
Aggregate tumor size
Low risk vs unstratified R-LR0.2080.0790.139
High risk vs unstratified R-LR0.0690.3700.281
Low risk vs unstratified RIO-RFA0.0680.0110.036
High risk vs unstratified RIO-RFA0.5950.8670.971
R-LR: Robotic liver resection; RIO-RFA: Robotic intraoperative radiofrequency ablation.
Full Size Table
Table 8 Log-rank test results comparing overall survival between unstratified and risk-stratified subgroups of the robotic liver resection group in the first recurrence group after propensity score matching
Aggregate tumor size
Complication
Low risk vs unstratified R-LR0.3200.145
High risk vs unstratified R-LR< 0.001< 0.001
Low risk vs unstratified RIO-RFA0.1880.357
High risk vs unstratified RIO-RFA0.0570.122
R-LR: Robotic liver resection; RIO-RFA: Robotic intraoperative radiofrequency ablation.
Full Size Table
Table 9 Log-rank test results comparing recurrence-free survival between unstratified and risk-stratified subgroups of the robotic liver resection group in the de novo group prior to propensity score matching
Platelet
Prothrombin time
Low risk vs unstratified R-LR0.1510.232
High risk vs unstratified R-LR0.0290.171
Low risk vs unstratified RIO-RFA0.7180.805
High risk vs unstratified RIO-RFA0.1060.240
R-LR: Robotic liver resection; RIO-RFA: Robotic intraoperative radiofrequency ablation.
Full Size Table
Table 10 Log-rank test results comparing recurrence-free survival between unstratified and risk-stratified subgroups of the robotic intraoperative radiofrequency ablation group in the first recurrence group after propensity score matching
Platelet
OP time
Complication
Low risk vs unstratified R-LR0.9710.8440.343
High risk vs unstratified R-LR< 0.001< 0.001< 0.001
Low risk vs unstratified RIO-RFA0.1430.2160.428
High risk vs unstratified RIO-RFA0.0900.2300.159
R-LR: Robotic liver resection; RIO-RFA: Robotic intraoperative radiofrequency ablation; OP: Operative procedure.
Full Size Table
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345